The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2014 | Latest data with ONO-4059 and ibrutinib
Prof Simon Rule, Plymouth Hospital, Plymouth, UK, discusses data presented at EHA 2014 on the second-generation oral BTK inhibitor, ONO-4059. One study presented relates to CLL, the other to non-Hodgkin’s lymphoma (NHL). In both studies, ONO-4059 shows promising results which might allow it to compete with ibrutinib. Prof Rule also outlines the benefits seen with ibrutinib in several haematological cancers, and a presents a poster showing 2-year ibrutinib toxicity data.
